



MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024

**April 11, 2025**

## FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute “forward-looking statements”. Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve several material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward - looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward - looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements because of various factors, including, but not limited to, the Company’s ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition, and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company’s control, include, but are not limited to: management’s expectations regarding the future business, objectives and, operations of the Company; the Company’s anticipated cash needs and the need for additional financing; the Company’s ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company’s expectations regarding its competitive position; the Company’s expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company’s ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company’s business and the markets in which it operates. Assumptions underlying the Company’s working capital requirements are based on management’s experience with other public companies.

Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

The following Management’s Discussion and Analysis (“MD&A”) of the Company should be read in conjunction with the Company’s Unaudited Consolidated Financial Statements for the period ended September 30, 2024, together with notes thereto (the “Financial Statements”). The Company’s Unaudited Consolidated Financial Statements for the period ended September 30, 2024, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). All amounts herein are presented in Canadian dollars, unless otherwise noted.

The Company’s Audited Consolidated Financial Statements and its Annual Information Form are

available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca)

## OVERALL PERFORMANCE

### Summary of Business

Leveljump Healthcare Corp. (the “Company”) is continued under the *Business Corporations Act* (Ontario). The Company’s registered head office is 52 Scarsdale Road, Suite 207, Toronto, Ontario, M3B 2R7. The Company’s website is [www.leveljumphealthcare.com](http://www.leveljumphealthcare.com).

The Company’s principal business activity is providing radiology services both by providing direct patient images and by providing Teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company’s radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital. The Company provides its direct to patient services at its Independent Healthcare Facilities (“IHF’s”).

### Results for Q3 2024

Total revenues for the third quarter were 4,448,956. Revenues for the nine-months ended September 30, 2024, were 12,927,183, a year over year increase of over 48%.

Teleradiology revenues were \$2,469,378 which was an increase of 2% compared to the third quarter of 2023.

Revenues from our IHF’s totalled 1,979,578 in the third quarter of 2024, a significant 360% increase over the third quarter of 2023.

### Discussion of Results

Third quarter 2024 performance was strong in terms of both the number of patient visits and total revenues. Many of our locations as well as our teleradiology operations are showing quarterly organic growth. The summer months historically can be the weakest quarter as many potential patients are away on vacation and staff book off personal and vacation time. Management is encouraged with the demand for its services in the quarter. At our IHF centres in Ontario demand for imaging continues to increase. The Company is working to hire additional staff at its imaging centres to meet the growing needs of the communities we operate in.

In Cobourg, we entered a lease for a new location to move the centre location in the fourth quarter. This new location is more accessible for patients and will allow the centre to work on growing its business by adding more ultrasound services. Our Cobourg location has also seen a big increase in demand for x-ray services.

September saw our new Toronto centre, Yonge Sheppard X-ray and Ultrasound open. Efforts are currently focused on marketing to the local community and reaching out to the local referring doctors’ offices. Management expects a gradual process to grow the revenues throughout the next 12 months.

Our IHF Centres in Alberta continue to show increased demand for services, with heavy increases in September. Following an expected pull back in the summer, the quarter ended with high patient volumes. Additional technologist hours for both ultrasound and x-ray, were added to the schedule to accommodate the increased demand.

Efforts were made throughout the third quarter to increase marketing efforts in Alberta, that are now paying off. Management focused on both community involvement, with local sponsorships and advertising. Additional outreach efforts to engage referring physician offices and area walk-in centres, were made.

Earlier in the year ADC brought back Pain Management services, which had not been provided at the locations since prior to COVID. A concise effort to build this business continues with some positive preliminary results. The Company anticipates increasing hours for this service, in the first quarter of 2025. ADC has also restored Bone Mineral Density (“BMD”) services. BMD is important for older patients and the detection of osteoporosis. The Company plans to work on expanding hours for this modality over the next few quarters. In Alberta, those over age 50, are encouraged to have a BMD exam every two years.

### Teleradiology

CTS saw a slight increase in its radiology reading for hospitals. Many hospitals are now allowing for a broader spectrum of imaging studies performed after hours, which has directly increased CTS volume. In the third quarter, one hospital gave notice to end its service with the company. The total value is approximately 3% of 2024 company wide revenue and not expected to have a significant negative impact. The end of the service is tied to the shortage of radiologist in Ontario. Teleradiology business opportunities are available, and the Company is working on ways to recruit additional radiologists, that include job fairs, advertising and referral bonus to our current radiologists.

### Telehospital

During the quarter, the Company continued to work on building out the infrastructure of the technology software. Focus has been put on development of the application, currently in phase one. Telehospital is a solution to assist with the nearly six million Canadians that do not have a primary physician. The telehealth services will be tied into our in-person centres, which we have incorporated into the design of our Yonge Sheppard Center.

### Financing and Share Issuances

During the quarter ended September 30, 2024 there were no new financing activities.

## SUMMARY OF QUARTERLY RESULTS

	Sep. 2024	Jun. 2024	Mar. 2024	Dec. 2023	Sep. 2023	Jun. 2023	Mar. 2023	Dec. 2022
Revenues	\$4,448,956	\$4,420,004	\$058,223	\$3,815,197	\$2,856,044	\$3,133,046	\$2,755,833	\$2,616,619
Profit/(Loss)	\$(5,421)	\$(111,219)	\$(673,358)	\$(216,708)	\$(1,593,641)	\$(237,635)	\$(239,646)	\$(37,187)
Profit/(Loss) per share	\$(0.000)	\$0.001	\$(0.007)	\$(0.002)	\$(0.017)	\$(0.003)	\$(0.003)	\$(0.000)
Profit/(Loss) per share diluted	\$(0.000)	\$0.001	\$(0.007)	\$(0.002)	\$(0.017)	\$(0.003)	\$(0.003)	\$(0.000)

In the first two quarters of 2023, revenues increased at both the Company IHF centres and its teleradiology business. There were a few reasons for the changes. The IHF centres had lengthy waiting lists, in response, the Company hired additional technologist and extended centre hours to meet the demand. As well in the first quarter of 2023 our radiology reading for our IHF centres, was brought in house and no longer outsourced and this led to additional revenue recognition. During these quarters, a new teleradiology client heavily increased its patient volumes which translated to increased business for the Company.

The third quarter of 2023 saw a decline in revenue as the summer months tend to slow down at times for IHF imaging centre patient volumes.

In the fourth quarter of 2023, the Company acquired ADC Imaging in Alberta. This led to a sharp increase in revenue as the acquisition occurred in early October and revenues were consolidated from that point forwards.

The first two quarters of 2024 saw increased revenue compared to the prior year, mainly from the affects of the ADC acquisition. Additionally, our IHF centres in Ontario were seeing increased waiting lists yet again, and the company was able to add some additional manpower for mammography and ultrasound services resulting in increased revenues from increased patient volumes.

The third quarter 2024 had a large increase in revenue compared to the prior year mainly due to the ADC acquisition. There was also a slight increase compared to the second quarter of 2024. Summer is usually a slower time, due to vacations by patients, staff and referring doctor's offices so the company did not anticipate a large quarter over quarter increase.

## LIQUIDITY AND CAPITAL RESOURCES

	24-Sep-30	23-Sep-30
Net and comprehensive loss	<b>(5,421)</b>	(1,593,641)
Items not involving current cash flows	<b>526,374</b>	129,059
Cash provided by operations	<b>520,953</b>	(1,464,582)
Net change in non-cash working capital	<b>(4,496)</b>	(506,722)
Cash provided by (used in) operating activities	<b>516,457</b>	(1,971,304)

Cash provided by (used in) investing activities	<b>(246,556)</b>	1,576,935
Cash provided by (used in) financing activities	<b>(527,921)</b>	845,227
Net change in cash and cash equivalents during the period	<b>(258,019)</b>	450,858
Cash and cash equivalents, beginning of period	<b>259,441</b>	457,264
<b>Cash and cash equivalents, end of period</b>	<b>1,422</b>	918,122

### Cash and Cash Equivalents

At September 30, 2024, cash and cash equivalents were \$1,422 compared to \$72,247 as at December 31, 2023.

### Operating Activities

Cash provided by operating activities was \$516,457 for the period ended September 30, 2024, compared to \$(1,971,304) for the period ended September 30, 2023. The increase in cash provided by operating activities was primarily due to an increase in revenues and operations from the ADC centres and increases in depreciation and amortization recognized by the Company.

### Investing Activities

Cash used by investing activities was \$(246,556) for the period ended September 30, 2024 compared to cash provided by investing activities of \$1,576,935 for the period ended September 30, 2023. Cash used by investing activities for the current period was primarily related to the building of the Company's new location at the Yonge Sheppard Centre.

### Financing Activities

Cash used in financing activities was \$(527,921) for the period ended September 30, 2024, compared to cash provided of \$845,227 for the period ended September 30, 2023. The cash used in financing activities was primarily due to the repayment of lease liabilities and bank debt, as well as some related party advances.

### Working Capital

The Company anticipates that its current working capital and the revenue it expects to generate from its continuing operations will be sufficient to satisfy its current debt obligations and working capital requirements for the next 12 months. The Company's ability to satisfy its non-current debt obligations will depend principally upon its future operating performance. The Company feels that the additional cash flows now being generated by its Alberta acquisition, and its newly opened Yonge Sheppard location have made the Company cash flow positive, while eliminating the additional spending on leasehold improvements and the Company expects to begin paying down accounts payable and improving its working capital into 2024 and 2025.

## CAPITAL STRUCTURE AND RESOURCES

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the quarter ended September 30, 2024.

The Company is not subject to externally imposed capital requirements other than those on its TD Long Term Debt which include priority rights against CTS, maintaining a debt to adjusted EBITDA ratio of 3.00 times as of September 30, 2024, and maintaining a debt service coverage ratio of not less than 115%.

The Company does not currently have any firm commitments for material capital expenditures.

Currently the Company does not have any firm commitments for the provision of new capital.

The Company's strategy includes organic growth through improved capacity utilization, opening new clinics and growth through strategic acquisition. To execute this strategy, the Company may need to access additional resources under existing loan arrangements or seek alternate sources of financing, including a new equity issuance.

The Company expects to continue to be able to meet all obligations as they become due using some or all the following sources of liquidity: cash flow generated from operations, existing cash and cash equivalents on hand, additional borrowing capacity under the revolving demand facilities. In addition, subject to market conditions, the Company may raise additional funding through equity financing. The Company believes that its capital structure will provide financial flexibility to pursue future growth strategies. The Company's ability to fund operating expenses and debt service requirements will depend on, among other things, future operating performance, which will be affected by general economic, industry, financial and other factors beyond the Company's control.

#### OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

#### RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. (See Note 19 in the Financial Statements).

#### THIRD QUARTER RESULTS

<b>Quarter Ended</b>	<b>September 30, 2024</b>	<b>September 30, 2023</b>
Total revenue	\$4,448,956	\$2,856,044
Gross profit	877,489	520,792
Operating Expenses	643,538	728,378
Net (loss) / income	(5,421)	(1,593,641)
Income/(Loss) per share–basic	\$(0.000)	\$(0.017)

During the third quarter of 2024, the Company's Diagnostic Imaging Services revenue increased by \$1,548,836 compared to the same period ending September 30, 2023 \$430,742, this increase was due to the acquisition and operation of four imaging centres in Alberta that the company did not own in the third quarter of 2023.

Physician Fees increased by \$426,030 in the current three-month period in 2024 compared to third quarter of 2023. this increase was due to the acquisition and operation of four imaging centres in Alberta that the company did not own in the third quarter of 2023.

In conjunction with the increased patient demand from the acquired centres, the Company experienced some increased costs associated with the necessary expenses to provide services to its patients. The most notable of these was an increased Cost of Labour by \$617,517 compared to a Cost of Labour of \$219,792 for the third quarter 2023, which represents the increased costs of technicians to service the additional patients seen in 2024 compared to 2023.

Other Cost of Services have dropped in the third quarter of 2024 by \$(54,805) compared to the same period in 2023 \$53,638, the decrease was due to receiving a large credit from one of our landlords, due to the delayed opening of our new centre.

In the third quarter of 2024, Depreciation increased by \$260,345 compared to the same period in 2023 \$35,480, increase is due to the increased volume of equipment from the newly acquired IHF Centres.

For the three months ended September 30, 2024, the Company recorded professional fees of \$316,572 a decrease of \$(116,960), compared to \$433,532 for the three months ended September 30, 2023. The decrease in professional fees was primarily due to less legal fees in 2024.

The increase in Interest Expenses during the third quarter of 2024 for \$195,277 compared to the same period in 2023 for \$59,411 was primarily related to interest on the increase in bank loans related to the purchase of the IHF centers in Alberta.

Primarily because of the above factors, the Company's gross profit increased by \$356,697 to \$877,489 for the three-month period ending September 30, 2024, versus gross profit of 520,792 for the same three-month period in 2023.

The net income for the three months ended September 30, 2024, was \$(5,421) compared to a net loss of \$(1,593,641) for the three months ended September 30, 2023.

#### Loss Per Share – Basic and Diluted

The income per share for the third quarter ended September 30, 2024, was \$(0.000) compared to a loss per share of \$(0.017) for the comparable period in 2023 on a basic and fully diluted basis.

## NINE MONTH RESULTS

<b>Period Ended</b>	<b>September 30, 2024</b>	<b>September 30, 2023</b>
Total revenue	\$12,927,183	\$8,686,850
Gross profit	2,292,785	1,688,244
Operating Expenses	2,327,931	2,309,342
Net (loss) / income	(789,816)	(2,148,193)
Loss per share–basic	\$(0.008)	\$(0.024)

During the first nine months of 2024 the Company suffered a decline in revenues from its existing Teleradiology clients due to a continuing reduced services at one of its larger client hospitals. Thus, Teleradiology sales decreased by \$212,624 compared to the same period in 2023. IHF revenues for the period were much higher compared to 2023 due to the 4 IHF locations in Alberta now being included in revenues. Demand for diagnostic imaging grew by \$4,452,957 compared to the same period last year. The total revenue increases were \$4,240,333.

In conjunction with the increased patient demand, the Company experienced increased costs associated with the necessary expenses to provide services to its patients. The most notable of these were physician fees which increased by \$1,017,547 as compared to the same period in 2023, and an increased Cost of Labour by \$1,518,088 compared to the same period in 2023, which represents the increased costs of technicians to service the additional patients.

In the nine-month period of 2024, depreciation increased by \$743,579 compared to the same period in 2023, and amortization by \$242,415 compared to the same period in 2023. The increases are due to the additional volumes of equipment and new leases as part of the purchase four Alberta IHF Centres.

For the nine months ended September 30, 2024, the Company recorded professional fees of \$1,400,139 up by \$10,539 compared to \$1,389,600 for the nine months ended September 30, 2023. The increase in professional fees for the nine months ended September 30, 2024, was primarily due to legal acquisitions.

The increase in Interest Expenses during the nine-months period of 2024 for \$730,139 compared to the same period in 2023 for \$31,980 was primarily related to interest on the bank loans related to the purchase of the four Alberta IHF locations.

Primarily because of the above factors, the Company's gross profit increased by \$604,541 to \$2,292,785 for the nine-month period ending September 30, 2024, versus gross profit of \$1,688,244 for the same nine-month period in 2023.

The net loss for the nine months ended September 30, 2024, was \$(789,816) compared to a net loss of \$(2,148,193) for the nine months ended September 30, 2023.

### Loss Per Share – Basic And Diluted

The loss per share for the nine months ended September 30, 2024, was \$(0.000) compared to a loss of \$(0.017) per share for the comparable nine-month period in 2023 on a basic and fully diluted basis

## PROPOSED TRANSACTIONS

The Company does not currently have any proposed transactions.

## CHANGES IN ACCOUNTING POLICIES

There have been no accounting policy changes in the first nine months of the year, and none are planned for the remainder of 2024.

## FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

During the period ended September 30, 2024, the Company had various bank loans outstanding as well as equipment loans. The interest rates on the loans vary from 6.28% to 9.99%. The bank loans are secured by a general security agreement representing a first charge on all the Company's present and future acquired assets. The equipment loan is secured by medical equipment specifically assigned by the Company. The bank loans have a 5-year term, are due in 2027, and are amortized over 10 years. The Equipment loans are amortized over 5 years and are due in 2028. (See Note 14 in the Financial Statements)

### Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. The Company's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represent revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As of September 30, 2024, three customers accounted for greater than 63% of the Company's trade receivable balance.

There have been no changes to this risk exposure from 2023.

The Company's maximum exposure to credit risk as of September 30, 2024, and December 31, 2023, was as follows:

	September 30, 2024	December 31, 2023
Cash and Cash Equivalents	\$ 1,422	\$ 72,247
Accounts Receivable	1,121,192	1,358,507
Due from Related Parties	1,548,629	696,152
Prepaid Expenses and Deposits	199,517	205,233
Total	\$2,870,760	\$ 2,332,139

## SHARE CAPITAL AND RESERVES

### Issued Share Capital

#### *Common Shares*

As at the date of filing this report the Company had 96,484,729 common shares outstanding. There are no other approved classes of common shares for the Company. (Financial Statements Note 16)

#### *Class A-Series 1 Preferred Shares (“A-1 Shares”)*

As at the date of filing this report the Company had 2,094,000 A-1 Shares issued and outstanding. (Financial Statements Note 16)

#### *Stock Options*

As at the date of filing this report the Company had 6,250,000 options issued and outstanding all are vested and exercisable into shares of common stock. (Financial Statements Note 17)

#### *Warrants*

As at the date of filing this report the Company had 7,200,000 common share purchase warrants issued and outstanding. (Financial Statements Note 18)

## FURTHER INFORMATION

More information about the Company can be found in the Company’s AIF which is available at [www.sedarplus.ca](http://www.sedarplus.ca) and the Company’s website.